Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia

DOI PDF 2 Citations
  • Julie A. E. Irving
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;
  • Amir Enshaei
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;
  • Catriona A. Parker
    Children’s Cancer Group, Institute of Cancer, Faculty of Medical & Human Sciences, The University of Manchester, Manchester, United Kingdom;
  • Rosemary Sutton
    Children’s Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia;
  • Roland P. Kuiper
    Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands;
  • Amy Erhorn
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;
  • Lynne Minto
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;
  • Nicola C. Venn
    Children’s Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia;
  • Tamara Law
    Children’s Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia;
  • Jiangyan Yu
    Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands;
  • Claire Schwab
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;
  • Rosanna Davies
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;
  • Elizabeth Matheson
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;
  • Alysia Davies
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;
  • Edwin Sonneveld
    Dutch Childhood Oncology Group, The Hague, The Netherlands;
  • Monique L. den Boer
    Dutch Childhood Oncology Group, The Hague, The Netherlands;
  • Sharon B. Love
    Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom;
  • Christine J. Harrison
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;
  • Peter M. Hoogerbrugge
    Dutch Childhood Oncology Group, The Hague, The Netherlands;
  • Tamas Revesz
    Department of Haematology-Oncology, SA Pathology at Women’s and Children’s Hospital and University of Adelaide, Adelaide, Australia; and
  • Vaskar Saha
    Children’s Cancer Group, Institute of Cancer, Faculty of Medical & Human Sciences, The University of Manchester, Manchester, United Kingdom;
  • Anthony V. Moorman
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;

Description

<jats:title>Key Points</jats:title> <jats:p>Chromosomal abnormalities predict outcome after relapse in BCP-ALL, and high-risk cytogenetics takes precedence over clinical risk factors. Patients with mutations or deletions targeting TP53, NR3C1, BTG1, and NRAS were associated with clinical high risk and an inferior outcome.</jats:p>

Journal

  • Blood

    Blood 128 (7), 911-922, 2016-08-18

    American Society of Hematology

Citations (2)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top